Dexcel Pharma Technologies Ltd.
|Dexcel Pharma Technologies Ltd. Patent applications|
|Patent application number||Title||Published|
|20120100199||METHOD FOR TREATING A PERIODONTAL DISEASE - Provided is a method for treating a periodontal disease affecting a periodontal pocket of a patient. The method includes inserting an oral delivery device into the periodontal pocket at a frequency of about once every 4 days to about once every 6 weeks. The oral delivery device is a controlled release solid unit dosage form suitable for insertion into a periodontal pocket of a patient, including a therapeutically effective amount of at least one anti-inflammatory agent, at least one antibacterial agent, or the combination of at least one anti-inflammatory agent and at least one antibacterial agent.||04-26-2012|
|20120100192||LOCAL THERAPEUTIC RELEASE DEVICE - An oral delivery device for the treatment of periodontal disease, the device being in a solid unit dosage form configured for insertion into a periodontal pocket of a patient. The device consists of: (a) a biodegradable pharmaceutically acceptable water-insoluble polymer in the form of a matrix; (b) a therapeutically effective amount of at least one anti-inflammatory agent dispersed within the matrix; (c) optionally a plasticizing agent; (d) optionally at least one of a wetting agent, a suspending agent and a dispersing agent; and (e) optionally an enzymatically biodegradable pharmaceutically acceptable water soluble polymer dispersed within the matrix. The biodegradable water-insoluble polymer is degradable by enzymatic degradation, physical disintegration or a combination thereof. Also disclosed is a periodontal implant comprising the device and a method for the treatment of periodontal disease comprising administering to a periodontal pocket of a patient in need of such treatment the delivery device.||04-26-2012|
|20100297226||MULTIPLE UNIT PHARMACEUTICAL FORMULATION - An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer.||11-25-2010|
|20090274758||Solid Composition for Intra-Oral Delivery of Insulin - The invention provides a solid composition for intra-oral delivery of insulin, comprising; insulin; a hydrophilic polymer matrix; and a phospholipid, providing insulin bioavailability of at least 5%.||11-05-2009|
|20080260818||Controlled Absorption of Statins in the Intestine - The present invention provides a controlled absorption formulation in which modified release of active ingredient preferentially occurs in the lower gastrointestinal tract, including the colon. The formulation supports a significantly higher bioavailability of the active ingredient into the body of the subject than can be achieved from the currently used conventional formulation, such that therapeutically significant plasma levels of statin are maintained for an extended period after administration. The formulation preferably features a core over which an outer coating is layered. The core is optionally and preferentially in the form of a tablet.||10-23-2008|
Patent applications by Dexcel Pharma Technologies Ltd.